调节器
医学
免疫抑制
癌症研究
细胞毒性T细胞
纤维化
肺
免疫学
抗体
免疫系统
免疫疗法
组织重塑
肿瘤进展
肿瘤细胞
转移
负调节器
封锁
主调节器
血管生成
肿瘤微环境
肺癌
作者
Aloña Agirre Lizaso,Maider Huici-Izagirre,Colm J. O’Rourke,Ekaterina Zhuravleva,Guido Carpino,Diletta Overi,Josu Urretabizkaia-Garmendia,Ibone Labiano,Ana Korosec,Beatriz Val,Diego Francesco Calvisi,Sumera Irie Ilyas,Joke M. M. den Haan,Patricia Aspichueta,Elizabeth Hijona,Adelaida La Casta,Raúl Jiménez-Agüero,Ana Lleo,Rocio I R Macias,Eugenio Gaudio
标识
DOI:10.1038/s41392-026-02657-w
摘要
Abstract Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary malignant tumors with poor prognosis and limited therapeutic options. Recent studies have highlighted the role of the immune system in the development and progression of intrahepatic CCA (iCCA). In this study, we investigated the role of the scavenger receptor MARCO in iCCA. Employing transcriptomic, spatial proteomic and histological analyses of human samples, MARCO was found on a specific subtype of tumor-associated macrophages linked to immunosuppression and extracellular matrix remodeling within the tumor microenvironment. High MARCO expression in human iCCA tumors correlated with worse overall survival, T cell dysfunction and increased collagen deposition. In line with this, MARCO expression was associated with a T H 2-skewed immune response and was increased in macrophages exposed to IL-4 and IL-13. Marco −/− mice were protected against iCCA development, exhibiting reduced tumor burden, fewer innate immune cells related to T H 2 responses and attenuated fibrosis. Moreover, Marco −/− mice exhibited lower levels of immunosuppressive markers on macrophages and cytotoxic T cells, resulting in improved overall survival and reduced lung metastases in an orthotopic tumor model. The use of an anti-MARCO antibody further reduced tumor volume in wild-type mice. This study identifies MARCO as a key regulator of immunosuppression, fibrosis and tumor progression in iCCA, and supports its potential as a novel therapeutic target for macrophage-directed immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI